Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies ; volume:24 ; number:1 ; day:8 ; month:10 ; year:2024 ; pages:1-12 ; date:12.2024
BMC neurology ; 24, Heft 1 (8.10.2024), 1-12, 12.2024
- Creator
-
Zivadinov, Robert
Keenan, Alexander J.
Le, Hoa H.
Ait-Tihyaty, Maria
Gandhi, Kavita
Zierhut, Matthew L.
Salvo-Halloran, Elizabeth M.
Ramirez, Abril Oliva
Vuong, Vivian
Singh, Sumeet
Hutton, Brian
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12883-024-03888-6
- URN
-
urn:nbn:de:101:1-2412252100454.029995240695
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zivadinov, Robert
- Keenan, Alexander J.
- Le, Hoa H.
- Ait-Tihyaty, Maria
- Gandhi, Kavita
- Zierhut, Matthew L.
- Salvo-Halloran, Elizabeth M.
- Ramirez, Abril Oliva
- Vuong, Vivian
- Singh, Sumeet
- Hutton, Brian
- SpringerLink (Online service)
Other Objects (12)
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
Current Disease-Modifying Therapies in Multiple Sclerosis
Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review
Disease-modifying treatments in Alzheimer’s disease
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis: a review of population-specific evidence from randomized clinical trials
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Current experimental disease-modifying therapeutics for multiple system atrophy
Lithium as a disease-modifying agent for prion diseases
Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001–2010
Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
Current Disease-Modifying Therapies in Multiple Sclerosis
Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review
Disease-modifying treatments in Alzheimer’s disease
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis: a review of population-specific evidence from randomized clinical trials
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Current experimental disease-modifying therapeutics for multiple system atrophy
Lithium as a disease-modifying agent for prion diseases
Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001–2010
Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
Current Disease-Modifying Therapies in Multiple Sclerosis
Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review
Disease-modifying treatments in Alzheimer’s disease
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis: a review of population-specific evidence from randomized clinical trials
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Current experimental disease-modifying therapeutics for multiple system atrophy
Lithium as a disease-modifying agent for prion diseases
Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001–2010